[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hip-fracture-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hip-fracture-surgery":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":5},"100631818","ai-based-rehabilitation-for-hip-and-knee-surgery-patients-100631818",false,"NCT07505628","AI-based Rehabilitation for Hip and Knee Surgery Patients","Evaluation of the Efficacy and Safety of AI-based Rehabilitation Exercise After Hip and Knee Arthroplasty","Inclusion Criteria:\n\n* Adult patients aged 19 years or older.\n* Patients scheduled to undergo hip or knee arthroplasty at Gangnam Severance Hospital or affiliated hospitals of Chung-Ang University Medical Center (Chung-Ang University Hospital, Gwangmyeong Hospital, Hyundai Hospital).\n* Patients with a preoperative Functional Ambulatory Category (FAC) stage of 4 or 5 (For hip fracture cases, pre-fracture FAC stage will be considered).\n* Patients capable of downloading and using mobile applications on smart devices (smartphones or tablets) independently without researcher assistance.\n* Patients who fully understand the study's purpose and procedures and have voluntarily signed the informed consent form.\n\nExclusion Criteria:\n\n* Individuals unable to perform exercises due to severe musculoskeletal pain.\n* Individuals with severe dizziness or poor vision that prevents them from following exercise videos provided by the digital treatment.\n* Individuals with visual impairment that causes difficulty in recognizing the monitor\u002Fdevice screen.\n* Individuals requiring long-term inpatient treatment due to unstable vital signs.\n* Individuals with partial or total lower-limb amputation due to trauma, disease, or congenital defects.\n* Individuals classified as vulnerable subjects (as defined by clinical research ethics guidelines).\n* Any other individuals deemed ineligible for participation at the discretion of the principal investigator.","ALL","19 Years",{"count":19,"type":20},106,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate the efficacy and safety of an AI-based home rehabilitation application (\"Exersite Rehab\") for patients who have undergone hip or knee arthroplasty(Total Knee Arthroplasty (TKA), Total Hip Arthroplasty (THA) or hip fracture surgery). Following surgery, effective rehabilitation is crucial for functional recovery; however, many patients face barriers to consistent in-hospital exercise. This interventional study divides participants into two groups to compare outcomes. The experimental group will perform a 12-week home-based rehabilitation program guided by an AI application that provides real-time posture correction and monitoring. In contrast, the control group will perform the same exercise protocol using traditional printed educational brochures.The primary objective is to determine if the AI-based digital healthcare solution significantly improves physical function, measured by the Functional Ambulatory Category(FAC), compared to conventional methods. Secondary outcomes including pain levels(Visual Analog Scale (VAS)) and joint-specific functional scores (Knee Society Score (KSS), Harris Hip Score (HHS)) will also be assessed over the 12-week period.",[26,27,28],"Total Knee Arthroplasty","Total Hip Arthroplasty (THA)","Hip Fracture Surgery",[30,31,32,33,34,35,36,37,38,39],"Arthroplasty","TKA","THA","Hip Fracture","Digital Therapeutics","AI Rehabilitation","Mobile Application","Home-based Exercise","Remote Monitoring","Physical Function","NOT_YET_RECRUITING","2026-03-26",{"date":43,"type":44},"2026-04-01","ACTUAL",{"date":46,"type":20},"2026-03-09",{"date":48,"type":20},"2028-12-31",{"name":50,"class":51},"Gangnam Severance Hospital","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100610521","phase-3-hip-fracture-surgery-arterial-and-venous-thrombotic-events-prevention-100610521","NCT07228663","Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","Rivaroxaban Plus Acetylsalicylic Acid Versus Standard of Care for Arterial and Venous Cardiovascular Prevention After Hip Fracture Surgery in Patients With Myocardial Injury: a Pilot Randomized Trial","HIPSTER-Pilot","Inclusion Criteria:\n\n* Age ≥45 years, received surgery for a hip fracture due to a low-energy mechanism, and myocardial injury (i.e., an elevated troponin measurement).\n\nExclusion Criteria:\n\n* Centers in which standard of care for VTE prophylaxis after hip fractures is ASA, alone or in combination with other drugs; patients with GFR \\\u003C15mL\u002Fmin; patients with drug interactions and conditions that prevent the use of the standard of care or intervention \\[Known allergy to the study drugs; pregnancy; an indication for anticoagulation, for dual antiplatelet therapy, for a P2Y12 inhibitor; already on rivaroxaban 2.5 mg twice daily + ASA before the fracture; bleeding diathesis that in the judgment of the investigator precludes the use of anticoagulant prophylaxis; history of significant hepatic disease (Child-Pugh B or C, see supplementary material) or any other condition that, in the judgment of the investigator, precludes the use of rivaroxaban; concomitant use of drugs that are strong inhibitors or strong inducers of P-glycoprotein (P-gp, e.g., systemic azole antimycotics, such as ketoconazole, and human immunodeficiency virus \\[HIV\\]-protease inhibitors, such as ritonavir) and\u002For Cytochrome P450 3A4 (CYP3A4)\\]; expected requirement for major surgery post-arthroplasty within 90 days; women Persons of childbearing potential who are not abstinent or do not use appropriate contraception or are breast-feeding; unable or unwilling to provide consent; previous participation in the HIPSTER trial; participation in another anticoagulant or antiplatelet study.","45 Years",{"count":62,"type":20},100,[64],"PHASE3","A third of patients undergoing surgery for a hip fracture develop a myocardial injury (i.e., an elevated troponin measurement), and these patients are at substantial risk of death and morbidity. Current prophylaxis strategies focus on preventing venous thromboembolism (VTE); however, arterial events are more common and carry a poor prognosis. The association of acetylsalicylic acid (ASA) 75-100 mg once daily and rivaroxaban 2.5 mg twice a day (the regimen used in the COMPASS trial) might prevent both VTE and arterial cardiovascular events. Among patients who have undergone hip fracture surgery and have evidence of myocardial injury, to explore the feasibility of a randomized controlled trial (RCT) comparing rivaroxaban 2.5 mg twice daily + low-dose ASA (75-100 mg) for 90 days, with standard VTE thromboprophylaxis for 30 days, for prevention of major cardiovascular events. The HIPSTER-Pilot is a multicenter, international, open-label, pilot RCT with blinded outcome adjudication. A total of 100 participants aged ≥45 years who received hip fracture surgery and experienced a myocardial injury will be randomized to receive either rivaroxaban 2.5 mg twice daily plus ASA 75-100 mg daily for 90 days or standard VTE prophylaxis with an anticoagulant for 30 days. The primary feasibility outcome will be the recruitment rate. Other feasibility measures include completeness of follow-up and adherence to the treatment. Exploratory clinical outcomes will be assessed. This pilot trial will provide information on the feasibility of conducting a larger RCT to evaluate the efficacy and safety of the COMPASS regimen for preventing arterial and venous thrombotic events after hip fracture surgery in patients who have had myocardial injury. The results of this feasibility study will inform the design of the full-scale trial.",[28,67,68],"Cardiovascular Prevention","Venous Thromboembolism (VTE)",[70,71,72,73,74,75],"rivaroxaban","acetylsalicylic acid","cardiovascular prevention","hip fracture surgery","myocardial injury","venous thromboembolism (VTE)","2025-11-13",{"date":78,"type":44},"2025-11-14",{"date":80,"type":20},"2025-12-01",{"date":82,"type":20},"2027-12-01",{"name":84,"class":51},"McMaster University",3]